ClinicalTrials.gg
CompletedNCT04795765Updated Dec 10, 2024

SpineJack System Postmarket Registry

An observational study in Osteoporotic Vertebral Compression Fractures, sponsored by Stryker Instruments. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by Stryker Instruments (part of Stryker) · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
261
Ages
18 Years and older
Sex
All
01

Study summary

This postmarket registry is intended to prospectively collect real world data to support ongoing safety and performance of the SpineJack system.

Read the detailed description

The SpineJack System Registry will employ a prospective, multicenter, observational, consecutive enrollment design. The sample size for this Registry will include at least 400 patients treated for VCFs across approximately 10 sites. A total of 240 patients will be treated with the SpineJack system and 160 patients will be treated with other vertebral augmentation (VA) procedures, such as BKP or VP. Sites within the U.S. may include healthcare professionals (HCPs) that are surgeons, pain physicians and/or interventional radiologists.

02

Conditions studied

  • Osteoporotic Vertebral Compression Fractures

Browse trials for

03

In context

Fractures, Compression

50 studies on the registry are indexed under Fractures, Compression; 10 are open to participants now.

This study's enrollment of 261 is above the median of 100 across 16 observational studies indexed under Fractures, Compression.

Browse Fractures, Compression studies →

Lead sponsor

Stryker Instruments is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All eligible patients that meet inclusion criteria.

Inclusion criteria

  1. 18 years of age or older
  2. Understand and sign the form (as applicable)
  3. Exhibit no altered mental status or language barrier that may prevent completion of the patient reported outcome (PRO) surveys following the procedure.
  4. VCF diagnosis made and/or confirmed at participating site.

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
261 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Patients treated with SpineJack system

    SpineJack system procedure

    Procedure: SpineJack system

  • Patients treated with vertebral augmentation

    Vertebral augmentation procedures may include either balloon kyphoplasty (BKP) or vertebroplasty (VP).

    Procedure: Balloon kyphoplasty · Procedure: Vertebroplasty

Interventions

  • ProcedureSpineJack system

    For use in the reduction of painful osteoporotic vertebral compression fractures.

  • ProcedureBalloon kyphoplasty

    Treatment of osteoporotic vertebral compression fractures.

  • ProcedureVertebroplasty

    Treatment of osteoporotic vertebral compression fractures.

06

What researchers measure

Primary outcomes

  1. Back pain

    The numeric rating scale consists of an eleven-point scale used for patient self-reporting of back pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable).

    Time frame: 12 months post-procedure

  2. Radiological outcomes

    Vertebral body height restoration

    Time frame: Immeditely post-procedure

  3. Radiological outcomes

    Adjacent level fractures

    Time frame: Immediately post-procedure

  4. Adverse events

    1. Incidence of adverse device effects (ADEs) and serious adverse device effects (SADEs) requiring surgical re-intervention or re-treatment at the treated level 2. Incidence of unanticipated ADEs 3. Incidence of procedure-related AEs

    Time frame: 12 months post-procedure

  5. Quality of life indices - Roland Morris Disability Questionnaire (RMDQ)

    24-item self-report questionnaire used in patients with mild to moderate disability due to acute, sub-acute or chronic low back pain

    Time frame: 12 months post-procedure

  6. Patient-Reported Outcomes Measurement Information System (PROMIS Global-10)

    10-item questionnaire that is used to assess general domains of health and functioning, including overall physical health, mental health, social health, pain, fatigue and overall perceived quality of life

    Time frame: 12 months post-procedure

07

Study locations

12 sites
  • San Diego Neurosurgery
    Encinitas, California 92024, United States
  • California Orthopedics and Spine
    Larkspur, California 94939, United States
  • Cleveland Clinic
    Stuart, Florida 34994, United States
  • St. Luke's IntermountainResearch Center
    Boise, Idaho 83702, United States
  • Dartmouth Hitchcock
    Lebanon, New Hampshire 03756, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Clinical Investigations
    Edmond, Oklahoma 73013, United States
  • Center for Diagnostic Imaging (CDI)
    Puyallup, Washington 98373, United States
  • Rainier Orthopedic Institute
    Puyallup, Washington 98374, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04795765
Collaborators
Talosix
Responsible party
Sponsor
First posted
Mar 12, 2021
Start date
Aug 19, 2019
Primary completion
Nov 11, 2024
Completion
Nov 11, 2024
Last update
Dec 10, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion